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HIV-RELATED RENAL DISEASE - A CLINICAL
AND PRACTICAL APPROACH IN THE SOUTH
AFRICAN CONTEXT
EPIDEMIOLOGY
The clinical determinants of HIVAN are heterogeneous,
although commonly described risk factors for its
development include black ethnic group, male gender,
injected drug use, a low CD4 count and a high viral load.
Although the exact pathogenesis is not completely
understood, two distinct features appear to be of
importance:
• molecular mechanisms related to genetic
predisposition, and
• HIV itself.
RISK FACTORS FOR HIVAN
PATHOGENESIS
Patients who are homozygous for a deletion mutation in
the CCR5 co-receptor appear to be protected from HIV
infection." It has been demonstrated that HIV-1 mRNA is
expressed in human renal epithelium and this transgenic
In South Africa the majority of patients with HIVAN are
black, although this may simply reflect the high prevalence
of HIV in this population group in general. However, in a
study from Cape Town Bates et 0/.' described 5 patients of
mixed race in a cohort of 22 biopsy-proven HIVAN cases.
Interestingly, patients with family members with renal
disease appear to have a higher risk of developing HIVAN.
It is possible that an inherited susceptibility to renal failure
is present in many blacks with HIV infection who
subsequently develop nephropathy.'
In the USA over 85% of cases of HIVAN occur in African-
Americans, and it is the third leading cause of end-stage
renal disease (ESRD) in blacks aged 20 - 64 years.'
patients with HIV and renal disease have limited or no
access to antiretroviral and renal replacement therapy
(including dialysis). Although such therapies are not
curative, they may slow disease progression and even
prolong survival.'
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Human immunodeficiency virus-related renal diseases
occur in up to lOO/a of patients infected with HIV. The
majority of such patients are black and the commonest
pathology seen is HIV-associated nephropathy [HIVAN).
This is a clinicopathological entity characterised by
proteinuria and rapidly developing renal failure and
histologically by a collapsing variant of focal and
segmental glomerulosclerosis with acute tubular
necrosis and mild interstitial inflammation. It may
progress rapidly to end-stage renal disease (within 6
months). HIVAN appears to be the commonest cause of
renal disease in HIV-infected patients in South Africa,
although the exact prevalence is unknown. The disease
affects predominantly black males, although it has been
described in patients of mixed race. Current thoughts
with regard to pathogenesis revolve around the role of
HIV in the renal epithelium and the effects of cytokines,
including transforming growth factor-beta and basic
fibroblast growth factor, on renal structures. Treatment
modalities available locally include corticosteroids,
angiotensin-converting enzyme (ACE) inhibitors and
where possible antiretroviral agents. The demographics
of the HIV/AIDS epidemic indicate that the risk pool for
HIVAN will continue to rise, and with it the prevalence of
renal failure.
Data from the USA suggest that 10% of HIV-infected
patients will develop HIV renal disease at some stage of
their infection (although usually late in the course of the
disease). From these data it is estimated that in the South
African context 650 000 people may well suffer from HIV
renal disease - frightening figures indeed. Furthermore,
South Africa is part of the developing world, so most
Of the South African population of 47 million an estimated
6.5 million people are infected by HIV, although the
prevalence is not universally agreed upon.'
Renal manifestations are an important component of HIV
disease, and renal disease contributes significantly to
morbidity and mortality in patients with HIV.
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expression results in cellular proliferation and is likely to
play a key role in the pathogenesis of HIVAN.' The presence
of HIV-l mRNA further suggests localised replication of
HIV-l in the kidney and the existence of a renal viral
reservoir.' Furthermore, upregulation of transforming
growth factor-beta (TGF-~) may cause loss of nephron
structure and sclerosis.'
PATHOLOGY
Although the classic pathological feature of HIVAN is the
collapsing form of focal and segmental glomerulosclerosis,
the affected glomeruli contain hypertrophied visceral
epithelial cells, large cytoplasmic vacuoles and numerous
protein resorption droplets. Such distortion results in an
increase in kidney size by up to 250/0. Glomerular
endothelial cells classically contain tubuloreticular
inclusions, the interstitium is oedematous with T-cell
infiltration, and Bowman's capsule can be dilated."
Importantly, a spectrum of other histological lesions are
associated with HIV infections. Lesions such as
mesangiocapillary glomerulonephritis (GN), post-infectious
GN, membranous GN, amyloid AA, and IgA nephropathy
make up to one-third of the diagnoses in renal biopsy
series, including those in South African patients""'"
CLINICAL PRESENTATION AND RISK FACTORS FOR
HIVAN
Although HIVAN may be the presenting manifestation of
AIDS, it usually occurs after a prolonged period of viral
infection often associated with high levels of HIV
viraemia." Cases have been described in which HIVAN has
occurred before HIV antibody seroconversionH
Patients typically present with nephrotic range proteinuria
and unrelenting progression to renal failure. Peripheral
oedema and hypertension are uncommon, although
patients with malignant hypertension have been
described." Besides proteinuria urinalysis is bland,
although in the uncommon proliferative GNs found in HIV
the sediment may contain red blood cell casts.
Unfortunately the correlation between clinical presentation
and underlying HIV renal pathology is poor and true
diagnosis is only possible on biopsy.
FACTORS PREDISPOSING TO PROGRESSION
Strong associations exist between increasing HIV RNA level
and decreasing CD4 Iymphocyte count and the presence of
proteinuria and occurrence of renal failure. Furthermore
the presence of coinfection with hepatitis C increases the
chance of progression."
EVALUATION OF HIV-INFECTED PATIENTS WITH
RENAL DYSFUNCTION
Even among patients with normal kidney function, the
presence of proteinuria indicates early glomerular disease.
Although no clinical practice guidelines exist for the
evaluation of HIV-infected patients with renal dysfunction,
considering the high incidence of HIVAN in such patients, it
would be appropriate to perform a simple urinalysis at their
initial visit. Annual follow-up examinations of individuals
in high-risk groups (see above) may be justified. Proteinuria
should be quantified with a protein/creatine ratio
performed on a spot urine sample, serological tests for
coinfection with hepatitis Band C and syphilis should be
done, and CD4 and HIV RNA levels should be measured if
facilities are available. Renal biopsy is warranted and
indicated in patients with significant proteinuria
(> 0.5 g/24 h) or progression of renal failure, and when a
definitive histological diagnosis will alter therapy.
ACUTE RENAL FAILURE IN HIV
Acute renal failure is well described in patients with HIV,
and possible causes are listed in Table I. Underlying
glomerular disease and disturbances in renal tubular
function predispose these patients to haemodynamic and
nephrotoxic insults. Prerenal azotaemia is the commonest
cause, although direct damage to the renal tubules from
nephrotoxic medications occurs frequently in hospitalised
patients. Tubulointerstitial nephritis as a result of allergic
reactions to medications is also well described. Importantly,
crystalluria and nephrolithiasis occur in relation to drugs
used to treat HIV directly and those used to treat associated
infections.





• Hypotension and sepsis
• Antibiotics: Aminoglycosides; amphotericin B




• Non-steroidal anti-inftammatory drugs (NSAIOs)
• Rifampicin and isoniazid IINH)
Renal obstruction [crystalluria and nephrolithiasis}
• Sulfadiazine; indinavir; acyclovir
HIV-positive patients presenting with acute renal failure
have a similar outcome to those who are not infected, so
HIV should NOT be an exclusion criterion when deciding on
acute renal failure therapy in such patients.
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TREATMENT
In the South African context there are few options for the
majority of patients with HIV and renal disease, particularly
HIVAN. Although there are no randomised clinical trials,
angiotensin-converting enzyme (ACE) inhibitors have
shown promise in the therapy of HIV and kidney disease
and are available in this country. Interestingly, ACE
inhibitors appear to mediate their effect in HIVAN via
mechanisms other than altered renal haemodynamics. By
inhibiting the angiotensin-II-mediated rise in TGF-~
(present in the kidneys of patients with HIVAN), ACE
inhibitors may slow the formation of sclerosis in the kidney
and thus slow the progression of renal failure."
The proteinuria-decreasing effects of ACE inhibitors have
long been recognised, and it seems logical to prescribe an
ACE inhibitor for patients with HIVAN.
Logic would seem to dictate that corticosteroids should not
be used in a patient with HIV. However, their use is
definitely advocated in HIV patients with nephropathies to
which they are known to respond, e.g. minimal-change GN
and aggressive interstitial nephritis related to concomitant
drug use. Their place in direct therapy is more controversial.
Observational studies have shown improved survival in
some patients, although relapses are common and when
they are used for prolonged periods there is a risk of
infection."" They should therefore be used judiciously,
while closely monitoring clinical response, and ideally with
the backing of a histological diagnosis. Common sense
would suggest the addition of preventive antibiotics such
as INH and trimethoprim-sulphamethoxazole (Bactrim),
although these drugs cause renal problems in their own
right
Antiretroviral therapy has been shown to slow the
progression of HIVAN, whether it consists of monotherapy
with zidovudine, protease inhibitors or highly active
antiretroviral therapy (HAARn.''''''' Patients who received
HAART have been found to maintain stable renal function,
whereas patients who did not required dialysis or died with
advanced renal failure. Monotherapy for HIV could induce
resistance and is not recommended, although with the
possibility that HAARTwill become more readily available in
South Africa, the treatment of HIVAN should be optimised.
Many of these drugs are renally cleared, so caution is
required when prescribing them to patients already in renal
failure. Furthermore, little information is available on
HAART medications and their clearance by dialysis.
Stavudine and nevirapine accumulate in renal failure and
are cleared by haemodialysis, whereas Saquinavir is poorly
removed and adjustment of the dose is needed.
HIV patients are excluded from State-funded long-term
dialysis programmes in South Africa, and although this
raises ethical issues, the grounds for such a ruling may not
be unfounded, particularly with regard to a resource as
scarce as dialysis. Patients who do receive dialysis have a
poor prognosis, with SQO,b mortality within the first year,
although this may improve if they receive HAART."
Infection and thrombosis are more common than in
patients without HIV infection, and the risk an HIV-positive
patient poses to staff and other patients should not be
forgotten. Peritoneal dialysis has similar problems in the
way of infection, and the fact that virus replicates in
peritoneal dialysis fluid may worsen the patient's systemic
viral load.
CONClUSION
As therapy for HIV becomes more readily available in South
Africa it is to be hoped that the prevalence of HIVAN and
renal disease related to this epidemic will decrease.
Currently available therapy is far from adequate, and
without HAART many patients will die of the renal illness.
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